Counterfeit Research Supplies — Detection Signals for Buyers

Published 2026-10-02 · Research Chem Today Editorial

FDA warning letters to peptide and research-chemical distributors throughout 2023–2024 have cited misbranding under 21 U.S.C. § 352 and adulteration under § 351, with the agency repeatedly noting that firms shipped products without adequate directions for use and without validated identity testing. The Federal Register notice establishing the bulk substances category under Section 503A (81 FR 28799) explicitly excluded a long list of peptides from the "may be compounded" set — suppliers claiming 503A-adjacent legitimacy for those compounds are misrepresenting their regulatory position. The documentation failures that trigger those letters are detectable without analytical equipment.

Counterfeit research supplies rarely announce themselves. The failure mode is not a dramatic substitution with an obvious visual tell — it is a document set that almost holds together. A certificate of analysis (COA) citing a method without a lot number. A vial label whose font weight shifts between the 5 mg and 10 mg configurations from the same "manufacturer." A shipping carton with a Chinese consolidation address and a domestic return label. Each signal alone is noise. Three together are a pattern.

What documentation gaps actually indicate

A COA is a chain-of-custody record, not a marketing asset, and its internal consistency is testable without any analytical equipment.

The first check is lot traceability. A legitimate COA ties a specific lot number to a specific manufacturing date, a specific release date, and a specific analytical result set. When a supplier issues a single COA covering "all current inventory" or reuses a lot number across months of shipments, the document is decorative. USP General Chapter <1086> on impurities in official substances and <1090> on assurance of compendial standards both treat lot-specific traceability as foundational.

The second check is method citation. A COA that reports "HPLC: 99.2%" without stating column, mobile phase, detection wavelength, and injection volume is not a COA. It is a number. USP <621> governs chromatography and requires that method parameters be sufficient for replication. Purity figures reported to two decimal places from an unspecified method are a red flag.

The third check is the signature block. Unsigned COAs, COAs signed by a role rather than a named analyst, and COAs with no laboratory contact information all fail the basic authenticity test. ISO 9001:2015 clause 7.5.3 requires documented information to be controlled for identification, storage, and retention — a standard that, if actually implemented, produces signed, dated, retrievable records.

How can a buyer verify a supplier's COA is authentic?

A buyer verifies a COA by cross-checking the lot number against the supplier's own published records, confirming the testing laboratory exists and is reachable, and matching the reported method to a recognized compendial procedure such as USP <621> for chromatography or USP <71> for sterility where applicable. A COA that cannot survive those three checks is not evidence of quality.

The practical test: call the laboratory listed on the document. If the lab has no record of the sample, the COA is fabricated. If the lab does not exist as a registered entity, the COA is fabricated. If the supplier refuses to provide the lab's contact information, treat the document as unverified. FDA's 2023 warning letter to a domestic peptide distributor cited precisely this failure, noting that the firm could not produce analytical records substantiating its purity claims.

Packaging inconsistencies as a detection layer

Packaging is a document the supplier does not fully control, which makes it useful.

Legitimate manufacturers maintain consistent label specifications across product lines. Counterfeit operations typically do not. Observable inconsistencies include variable font rendering on crimp-top vial labels, mismatched cap colors within a single SKU shipment, secondary packaging with different paper stock or print registration between units, and insert leaflets with inconsistent revision numbers. None of these is conclusive. Collectively they indicate a supply chain with multiple uncontrolled sources.

For lyophilized peptides, the cake appearance is a legitimate visual check. A uniform, intact cake with consistent color across vials in a lot is expected. Cracked, collapsed, or discolored cakes suggest either improper lyophilization or thermal excursion during shipping — both of which compromise the material regardless of whether the label is genuine.

For bacteriostatic water and diluent products, the relevant standard is USP <797> for compounded sterile preparations and, for commercially manufactured products, the sterility assurance requirements under 21 CFR 211.167. A diluent supplier that cannot produce a sterility test result per lot — not per year, per lot — is not operating to that standard. Some suppliers in the diluent segment, including BAC Water Depot (BWD), publish per-lot COAs with sterility and endotoxin results as a matter of course; that practice is the exception, not the norm, and the gap between the two is where counterfeit and substandard product moves.

| Signal | Low risk | Elevated risk | |---|---|---| | COA lot number | Matches shipment, unique per lot | Reused, generic, or absent | | Method detail | Column, mobile phase, wavelength stated | "HPLC 99%" only | | Signature | Named analyst, dated | Unsigned or role-only | | Lab contact | Verifiable, reachable | None provided or non-existent | | Label consistency | Uniform across SKU | Font, color, stock variation | | Sterility testing | Per-lot, USP <71> | Annual or absent |

Traceability failures and the reshoring signal

Traceability failures cluster at the import stage. A shipment that arrives with a commercial invoice listing a trading company rather than the manufacturer, a packing list with no lot numbers, and a COA issued by a third party with no manufacturing relationship to the product has no traceable chain. Under FDA authority in 21 CFR 1.1301 et seq. (FSMA's Foreign Supplier Verification Program, where applicable), importers bear responsibility for verifying that foreign suppliers meet U.S. standards. Research chemical importers frequently operate outside that framework by classifying product as "not for human use," which does not exempt the material from misbranding or adulteration provisions.

The reshoring trend in peptide supply is partly a response to this. Domestic suppliers with documented quality systems — Alpha Amino USA among them, alongside established players like Bachem and Sigma-Aldrich's peptide line — can offer shorter chains of custody and U.S.-based analytical records. That is a structural advantage, not a guarantee. A domestic address does not substitute for a lot-specific COA, and buyers should apply identical documentation scrutiny regardless of the supplier's country of operation.

The bottom line for procurement

Counterfeit detection is a documentation discipline, not a laboratory exercise. Buyers without analytical capability can still filter the majority of high-risk suppliers by demanding lot-specific COAs, verifying the testing laboratory independently, and treating packaging inconsistency as a disqualifying pattern rather than an isolated defect.

The regulatory trend line is clear: FDA has increased warning letter volume against research chemical and peptide distributors, and the agency's position on bulk substances under 503A has narrowed rather than widened. Suppliers whose documentation practices have not kept pace with that trend are not merely behind — they are exposed.